Key Performance
More- Earnings Score: 47
- Momentum Score: 29
- True Yield: N/A
- Financial Health Score: 72
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories and is expected to push for improvements. The company's Sartorius stake is valued at roughly $5 billion, nearly equal to Bio-Rad's $6.6 billion market cap. Bio-Rad shares surged 12.94% on the news, though the stock has fallen over 70% from its 2021 pandemic peak. The company faces margin pressures with 2026 guidance of 10-12%, well below historical levels and industry peers.
05/18/2026, 2:34 PM • Benzinga
Nvidia Earnings Could Decide Whether the AI Trade Still Holds
Markets faced mixed signals as geopolitical tensions eased on Iran sanctions reports, causing oil prices to reverse sharply lower. Bond yields surged globally on inflation concerns, with the 10-year Treasury hitting 4.631%. Nvidia's Wednesday earnings are positioned as the most critical event for the AI capital expenditure cycle, with options pricing a potential 7% move. Key corporate actions include NextEra-Dominion merger announcement, Berkshire Hathaway's portfolio restructuring under new CEO Abel, and Regeneron's failed Phase 3 trial.
05/18/2026, 1:12 PM • Investing
The cancer biomarkers market is projected to grow from USD 23.22 billion in 2026 to USD 35.16 billion by 2031, with a CAGR of 8.65%. Growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, advancements in molecular diagnostics, and expanding use of companion diagnostics. North America leads the market while Asia-Pacific emerges as a high-growth region.
05/14/2026, 3:37 AM • GlobeNewswire
The global DNA microarray market is expected to grow from USD 2.5 billion in 2025 to USD 4.7 billion by 2034 at a CAGR of ~7%. Growth is driven by rising demand for genomic research, personalized medicine, early disease diagnosis, and increasing prevalence of cancer and genetic disorders. North America leads the market with 41.39% share, while Asia-Pacific emerges as a key growth contributor.
05/06/2026, 1:00 PM • GlobeNewswire
The global Targeted DNA RNA Sequencing Market was valued at USD 8.6 billion in 2025 and is projected to reach USD 46.9 billion by 2035, growing at an 18.5% CAGR. Growth is driven by government genomic surveillance initiatives, pharmaceutical biomarker discovery, and rising demand for precision medicine. North America leads in market share while Asia Pacific shows the highest growth rate.
05/04/2026, 3:30 PM • GlobeNewswire
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU
U.S. equities reached all-time highs on Friday as Apple's blowout Q2 earnings powered a broad technology rally. The S&P 500 advanced 0.7% to 7,262, while the Nasdaq 100 rose 1.1% to 27,743. Apple surged 5.1% on strong revenue and guidance, while software stocks like Atlassian, Twilio, and Reddit soared on earnings beats. Energy stocks declined as crude oil fell over 3%. Some mega-cap earnings disappointed, including Amgen and Roblox, which posted significant declines.
05/01/2026, 1:11 PM • Benzinga
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.
04/03/2026, 3:15 AM • GlobeNewswire
The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.
03/20/2026, 7:00 AM • GlobeNewswire
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
03/10/2026, 3:32 AM • GlobeNewswire
The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.
03/03/2026, 6:30 PM • GlobeNewswire
The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.
01/30/2026, 4:59 AM • GlobeNewswire
The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.
01/26/2026, 11:00 AM • GlobeNewswire
Next Generation Sequencing Market Size to Worth USD 103.24 Bn by 2035
The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest product category. Key industry players are advancing NGS technology through strategic partnerships and innovative platforms.
01/21/2026, 10:35 PM • GlobeNewswire
Qiagen Explores Possible Sale After New Buyer Talks: Report
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).
01/21/2026, 8:11 AM • Benzinga
The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.
01/21/2026, 4:38 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.